Radiopharm Theranostics Limited (AU:RAD) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Radiopharm Theranostics has announced promising results from a study on their imaging agent 68Ga-RAD 301, indicating its potential in accurately visualizing pancreatic cancer tumors and metastases. The study, which involved 44 patients, highlighted the agent’s safety and effectiveness, paving the way for its use in improving pancreatic cancer diagnostics. Currently, a Phase I trial is underway to further explore its capabilities.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Hold Your Horses,’ Says Jefferies About Apple Stock
- All Eyes on Nvidia Stock Ahead of Earnings; Here’s What Oppenheimer Expects
- ‘The Golden Path Is Within Reach,’ Says Daniel Ives About Tesla Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
